SCHEMBL24933017

SCHEMBL24933017

NC(=O)c1cc(-c2ccc(OCC3COCCOC3)cc2)c(C(F)(F)F)[nH]c1=O

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PRKAB2 O43741 1/20 0.42
PRKAG1 P54619 1/20 0.42
PRKAA2 P54646 1/20 0.42
PRKAA1 Q13131 1/20 0.42
PRKAG3 Q9UGI9 1/20 0.42
PRKAG2 Q9UGJ0 1/20 0.42
PRKAB1 Q9Y478 1/20 0.42
XDH P47989 4/20 0.42
PARP10 Q53GL7 7/20 0.38
PARP15 Q460N3 6/20 0.38
SCN8A Q9UQD0 1/20 0.37
HSD17B1 P14061 3/20 0.36
HSD17B2 P37059 3/20 0.36
PARP2 Q9UGN5 2/20 0.36
FFAR4 Q5NUL3 2/20 0.35
CHEK2 O96017 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24933589 0.94 XDH (0.49) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL24933470 0.93 XDH (0.44) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL24932946 0.90 XDH (0.42) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL30240888 0.90 GPR84 (0.42) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL24933551 0.90 GPR84 (0.42) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL24933044 0.87 PRKAB2 (0.37) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL24933356 0.87 PARP10 (0.52) PARP10PARP15PARP2FFAR4CHEK2
SCHEMBL24933737 0.87 IRAK4 (0.42) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL24933633 0.86 PARP10 (0.53) PARP10PARP15PARP2FFAR4CHEK2
SCHEMBL24933840 0.85 PRKAB2 (0.46) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373809-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS Novartis AG (CH) 2024-05-29 EP claimed
CN-117980292-A Substituted pyridone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2024-05-03 CN claimed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO claimed
EP-4373809-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS Novartis AG (CH) 2024-05-29 EP disclosed
CN-117980292-A Substituted pyridone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2024-05-03 CN disclosed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO disclosed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO disclosed